These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Six-month buprenorphine-naloxone treatment is associated with neurocognitive function improvement in opioid dependence. Ghosh A; Mahintamani T; Rana DK; Basu D; Mattoo SK Indian J Psychiatry; 2022; 64(2):199-208. PubMed ID: 35494328 [TBL] [Abstract][Full Text] [Related]
3. Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs. Scott TM; Arnsten J; Olsen JP; Arias F; Cunningham CO; Rivera Mindt M Addict Sci Clin Pract; 2021 Oct; 16(1):64. PubMed ID: 34689841 [TBL] [Abstract][Full Text] [Related]
4. Neurocognitive functions in patients on buprenorphine maintenance for opioid dependence: A comparative study with three matched control groups. Saroj R; Ghosh A; Subodh BN; Nehra R; Mahintamani T; Rana DK; Basu D Asian J Psychiatr; 2020 Oct; 53():102181. PubMed ID: 32526693 [TBL] [Abstract][Full Text] [Related]
5. Neuropsychological function is improved among opioid dependent adults who adhere to opiate agonist treatment with buprenorphine-naloxone: a preliminary study. Scott TM; Rivera Mindt M; Cunningham CO; Arias F; Coulehan K; Mangalonzo A; Olsen P; Arnsten JH Subst Abuse Treat Prev Policy; 2017 Nov; 12(1):48. PubMed ID: 29141650 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial. Webster L; Hjelmström P; Sumner M; Gunderson EW J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785 [TBL] [Abstract][Full Text] [Related]
7. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097 [TBL] [Abstract][Full Text] [Related]
8. Comparison of neonatal outcomes in pregnant women undergoing medication-assisted treatment of opioid use disorder with methadone or buprenorphine/naloxone. Petrich M; Battin M; Walker E; Brown M; Abdelwahab M; Ma'ayeh M; Rood KM J Matern Fetal Neonatal Med; 2022 Dec; 35(26):10481-10486. PubMed ID: 36202398 [TBL] [Abstract][Full Text] [Related]
9. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter. Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641 [No Abstract] [Full Text] [Related]
10. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States? Rhee TG; Rosenheck RA Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111 [TBL] [Abstract][Full Text] [Related]
11. Secondary Analysis of Pain Outcomes in a Large Pragmatic Randomized Trial of Buprenorphine/Naloxone Versus Methadone for Opioid Use Disorder. Shulman M; Luo SX; Campbell ANC; Scodes J; Pavlicova M; Broffman A; Saxon AJ; Nunes EV J Addict Med; 2020; 14(5):e188-e194. PubMed ID: 32039934 [TBL] [Abstract][Full Text] [Related]
12. HIV clinic-based buprenorphine plus naloxone versus referral for methadone maintenance therapy for treatment of opioid use disorder in HIV clinics in Vietnam (BRAVO): an open-label, randomised, non-inferiority trial. Korthuis PT; King C; Cook RR; Khuyen TT; Kunkel LE; Bart G; Nguyen T; Thuy DT; Bielavitz S; Nguyen DB; Tam NTM; Giang LM Lancet HIV; 2021 Feb; 8(2):e67-e76. PubMed ID: 33539760 [TBL] [Abstract][Full Text] [Related]
14. Impact of naloxone education for patients receiving buprenorphine-containing prescriptions indicated for opioid use disorder at an independent community pharmacy. Hines KL; Garofoli GK; Garofoli MP; Elswick BM; Winstanley EL J Am Pharm Assoc (2003); 2020; 60(6):e205-e214. PubMed ID: 32800678 [TBL] [Abstract][Full Text] [Related]
15. The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale. Socias ME; Ahamad K; Le Foll B; Lim R; Bruneau J; Fischer B; Wild TC; Wood E; Jutras-Aswad D Contemp Clin Trials; 2018 Jun; 69():21-27. PubMed ID: 29627621 [TBL] [Abstract][Full Text] [Related]
16. The impact of buprenorphine/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients. Edelman EJ; Chantarat T; Caffrey S; Chaudhry A; O'Connor PG; Weiss L; Fiellin DA; Fiellin LE Drug Alcohol Depend; 2014 Jun; 139():79-85. PubMed ID: 24726429 [TBL] [Abstract][Full Text] [Related]
17. Developing A Rapid Transfer from Opioid Full Agonist to Buprenorphine: "Ultrarapid Micro-Dosing" Proof of Concept. Azar P; Mathew N; Mahal D; Wong JSH; Westenberg JN; Schütz CG; Greenwald MK J Psychoactive Drugs; 2023; 55(1):94-101. PubMed ID: 35152847 [TBL] [Abstract][Full Text] [Related]
18. Time to include buprenorphine-naloxone combination in the WHO Model List of Essential Medicines. Balhara YP J Opioid Manag; 2013; 9(4):237. PubMed ID: 24380101 [No Abstract] [Full Text] [Related]
19. Medications for management of opioid use disorder. Koehl JL; Zimmerman DE; Bridgeman PJ Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869 [TBL] [Abstract][Full Text] [Related]